A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia

The use of unmanipulated graft is increasingly adopted in the setting of allogeneic hematopoietic stem cell transplantation from haploidentical family donors (haplo-SCT) in acute leukemia (AL). We analyzed the outcome of 229 adult patients with de novo AL, who received an unmanipulated haploidentical transplant as their first allo-SCT between 2007 and 2011. Median follow-up was 30 months. Disease status at transplant was: first complete remission (CR1) for 77, second CR (CR2) for 56, and advanced for 96 patients. One hundred and seventy-one patients received in vivo T-cell depletion by monoclonal antibodies (75%). The 60-day cumulative incidence (CI) of engraftment was 93 +/- 2%. The 100-day CI of acute graft-versus-host disease (GvHD) was 32 +/- 3% for grade II-IV, 12 +/- 3% for grade III-IV. The 3-year CI of chronic GvHD was 34 +/- 3%. The 3-year CI of non-relapse mortality was 31 +/- 4% with in vivo T-cell depletion and 17 +/- 5% without. At 3 years, for patients transplanted in CR1, CR2 or advanced disease leukemia-free survival was 44 +/- 6, 42 +/- 7 and 12 +/- 3%, overall survival was 55 +/- 6, 51 +/- 7 and 14 +/- 4% and CI of relapse was 32 +/- 6, 24 +/- 6 and 61 +/- 5%, respectively. These data suggest that unmanipulated haplo-SCT is a valid treatment option for adult AL patients in complete remission lacking a matched donor.